SEC Tracker
Get the app

Tempest Therapeutics TPST

Tempest Therapeutics appoints new CFO

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Ms. Stephanie Horn-Warnock appointed as CFO, effective October 26, 2026
  2. Ms. Horn-Warnock has 14 years of experience in finance and accounting
  3. CFO will be paid $450 per hour plus expenses and 5% indirect cost allocation
  4. No family ties or arrangements between new CFO and company executives

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Tempest Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing cites the departure of Ms. Constance Ames as Chief Financial Officer and Principal Financial and Accounting Officer, effective immediately.
  2. Ms. Stephanie Horn-Warnock was appointed to these roles, effective October 26, 2026.
  3. Ms. Horn-Warnock has over 14 years of experience in financial leadership roles across multiple industries.
  4. She previously worked at ROM Technologies Inc. as Vice President of Finance from January 2024 to September 2026.
  5. During that time, she managed accounting, finance, and regulatory compliance functions.
  6. She also served as Controller of Diasome Pharmaceuticals, Inc. and Assistant Controller of Aspargo Labs, Inc. since March 2026.

6 of 6 claims matched the filing text.

From the filing

Item 5.02. Departure of Directors or

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Financial Officer and Principal Financial and Accounting Officer

On October 26, 2026, Ms. Constance Ames confirmed to Tempest Therapeutics, Inc. (the "Company") that she would be resigning from her position as Chief Financial Officer of the Company and from any and all other positions she holds with the Company for personal considerations unrelated to the Company, effective immediately.1

Appointment of Chief Financial Officer and Principal Financial and Accounting Officer

On October 26, 2026, the Board of Directors of the Company (the "Board") appointed Ms. Stephanie Horn-Warnock as Chief Financial Officer, Principal Financial and Accounting2

Officer, Treasurer, and Corporate Secretary of the Company, effective immediately.2

Ms. Horn-Warnock, 37, is an experienced financial executive with more than 14 years of experience in accounting, financial reporting, auditing and financial management across the healthcare, pharmaceutical, medical technology, behavioral health and renewable energy industries.3 Since March 2026, she has served in financial leadership and consulting roles through Stout Risius Ross, LLC, including as Controller of Diasome Pharmaceuticals, Inc. and Assistant Controller of Aspargo Labs, Inc.6, and as an accounting and financial reporting consultant to Lomond Therapeutics Holdings, Inc. From January 2024 to September 2026, Ms. Horn-Warnock was the Vice President of Finance at ROM Technologies Inc.4, where she led the company's accounting and finance functions, including financial planning and analysis, treasury, financial reporting and regulatory compliance.5 She also oversaw the company's annual audits, internal controls and equity reporting. From 2022 to 2024, she served as Senior Manager of Accounting and Assistant Controller at Palmetto Solar, LLC. From 2021 to 2022, she was Acco

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. ProMIS Neurosciences PMN public float $30M, Jun 30, 2025
  2. Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025
  3. Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
  4. Rockwell Medical RMTI public float $29M, Jun 30, 2025
  5. Champions Oncology CSBR public float $29M, Oct 31, 2025